Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatmentHilma J. van der Horst, Tuna Mutis, Daniella R. A. I. Berry et al.|Blood Cancer Journal|2021Cited by 95
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trialMartine E.D. Chamuleau, Marie José Kersten, Coreline N. Burggraaff et al.|Haematologica|2019Cited by 53